Triptolide Inhibits Tonsillar IgA Class Switching by Upregulating FDC-SP in IgA Nephropathy

Li, Huining; Kong, Dan; Yao, Guo‐Dong; Yang, Xu; Cao, Yan; Yang, Xinxin; An, Xushu; Li, Haibo; Li, Xiaomei; You, Qi; Zhang, Lei; Miao, Shusheng; Chen, Hui; Geng, Jiao; Jin, Xiaoming; Meng, Hongxue

doi:10.2139/ssrn.3321480

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the pathogenesis of immune complex deposition in glomeruli due to abnormal body immunity is widely recognized, opinions differ on whether immunosuppressive agents should be used alone or in combination in the treatment of IgA nephropathy [33,34]. e 2012 KDIGO guidelines recommend 6 months of glucocorticoid therapy for patients with GFR >50 ml/min and persistent urinary protein >1 g/d despite 3-6 months of supportive therapy [35,36]. However, no treatment recommendations are available for patients with proteinuria, GFR <50 ml/min, and not in ESRD.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Glycosides of Tripterygium wilfordii Combined with Renin-Angiotensin System in the Treatment of IgA Nephropathy: A Systematic Review and Meta-Analysis

Chen¹,

Zhang²,

Li³

et al. 2022

Emergency Medicine International

View full text Add to dashboard Cite

Background. IgA nephropathy (IgAN) is currently the most common primary glomerular disease, accounting for approximately 36.7% to 58.2% of primary glomerular disease in kidney biopsies in China. Definitive diagnosis depends on immunopathological examination of the kidney. The prognosis of this disease was generally considered to be good, but recent studies have found that about half of patients can progress to end-stage renal disease within 30 years of onset. Because the pathogenesis is unknown, there is no specific treatment. Objective. To evaluate the efficacy and safety of glycosides of Tripterygium wilfordii (GTW) in combination with renin-angiotensin system (RAS) inhibitors for the treatment of IgAN. Methods. Search Embase, Pubmed, Cochrane, CNKI, Web of Science, Wanfang, and VIP for all randomized controlled trials (RCTs) on treating IgAN with RASI from the self-built database to December 2021. Relevant data were searched and collected separately by two reviewers. The Cochrane risk of bias model was used for quality assessment, and RevMan 5.3 was used for data analysis. Results. Thirteen Chinese publications with a total of 958 patients were finally included. There was no statistically significant difference in baseline information (including laboratory data and clinical parameters) between the two groups of patients. The urine protein quantification in both groups showed a significant decreasing trend as the treatment duration increased. At 3, 6, 9, and 12 months after treatment, urine protein was significantly lower than the baseline value in both the observation and control groups (P < 0.05). During the follow-up period, there was no statistical difference in blood creatinine (Scr) and eGFR values between the two groups compared with the baseline values (P > 0.05). Patients with CKD stage 2 achieved a higher remission rate compared with patients with CKD stage 3, with a statistically significant difference (P < 0.05), and the difference between the two groups was not significant for patients in the same stage. There was no statistically significant difference in the total effective rate between the two groups (P > 0.05). During the follow-up period, there was no statistically significant difference in urine protein quantification, Scr, and eGFR between the two groups. In terms of the incidence of adverse reactions, the observation group was less than the control group, and there was a significant difference between the two groups (P < 0.05). Conclusion. GTW combined with RASI is one of the safe and effective treatment modes for IgAN nephropathy. It can not only effectively reduce the excretion of urinary protein in patients and delay the progression of chronic kidney disease but also has less serious side effects and is well tolerated by patients, so it can be a new choice of therapeutic drugs for this group of patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Glycosides of Tripterygium wilfordii Combined with Renin-Angiotensin System in the Treatment of IgA Nephropathy: A Systematic Review and Meta-Analysis

Chen¹,

Zhang²,

Li³

et al. 2022

Emergency Medicine International

View full text Add to dashboard Cite

show abstract

“…TNF-α and IL-1β stimulate human FDCSP gene transcription by targeting YY1, GATA, C/EBP2, and C/EBP3 in the FDCSP gene promoter [ 29 ]. FDCSP can regulate IgA production [ 30 , 31 , 32 ]. FDCSP is also expressed in the periodontal ligament [ 33 ], and its abnormally high expression promotes the formation of osteoclasts [ 34 , 35 ].…”

Section: Discussionmentioning

confidence: 99%

FDCSP Is an Immune-Associated Prognostic Biomarker in HPV-Positive Head and Neck Squamous Carcinoma

Shao

Huang

et al. 2022

Biomolecules

View full text Add to dashboard Cite

Background: Head and neck squamous carcinoma (HNSC) poses a major threat to human life. The role of human papillomavirus (HPV) infection in the initiation and progression of HNSC is becoming more widely accepted. HPV-positive (HPV+) HNSC has shown unique responses to cancer therapies, which may be due to differences in immune cell infiltration. It is critical to determine how the immune responses to HPV in HNSC are regulated. Methods: Transcriptome data of HNSC from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) database were analyzed. Then, the CIBERSORT algorithm was used to calculate immune cell infiltration in HNSC. FDCSP expression level was detected by qPCR in the HNSC tissues collected from the Nanfang Hospital. Results: Follicular dendritic cell secreted protein (FDCSP) was highly expressed in HPV+ HNSC, and higher expression of FDSCP was associated with a favorable prognosis. In HPV+ HNSC samples, FDCSP significantly increased the proportion of T follicular helper cells (TFHs). FDCSP expression was also found to be associated with TP53 mutation status in HPV+ HNSC. The function of FDCSP was intimately connected to chemokine pathways, particularly with the C-X-C motif chemokine ligand 13 (CXCL13). We verified that the high expression of FDCSP in HPV+ HNSC and higher FDCSP is closely related to prognosis in HNSC samples we collected by qPCR. Conclusions: Collectively, these findings may provide fresh evidence that FDCSP is a potential chemokine-associated prognostic biomarker in HPV+ HNSC.

show abstract

“…[23] The occurrence of IgAN is associated with tonsillitis, which enhances the polymeric galactose-deficient IgA1 (Gd-IgA1) production via IgA class switching and immuno-activation. [24] The tonsillectomy has been one of the hotspots in IgAN therapy, but the results of studies from Asia and Europe drew diametrically opposite conclusions. [25][26][27][28] The data from several cross-sectional studies in China showed that in IgAN patients, the chronic pharyngitis is around 62%-64%, and patients who had two or more respiratory mucosal symptoms accounted for 66.7%.…”

Section: Theoretical Basis Of Iga Nephropathy Treated By Traditional Chinese Medicinementioning

confidence: 99%

“…After 6 months of treatment, the total effective rate in the test group was better than that in the control group (77.5% vs. 56.4%). [36] Chinese herbal compounds focusing on dispelling wind and eliminating dampness Chen et 24-hour urinary protein quantity and serum creatinine were reduced and glomerular filtration rate (eGFR) was increased; however, the overall improvement was seen in the treatment group compared with the control group (P < 0.05). [37] A retrospective study conducted by Yu et al included 356 patients treated with Chinese herbal medicines for dispelling wind dampness.…”

Section: Theoretical Basis Of Iga Nephropathy Treated By Traditional Chinese Medicinementioning

confidence: 99%

Traditional Chinese medicine in treating IgA nephropathy: from basic science to clinical research

Wang

Lang

et al. 2021

Journal of Translational Internal Medicine

View full text Add to dashboard Cite

IgA nephropathy (IgAN) is a major cause of chronic kidney disease (CKD) and end-stage renal disease worldwide. Currently, clinical interventions for IgAN are limited, and many patients seek out alternative therapies such as traditional Chinese medicine (TCM). In the last several years, TCM has accumulated ample application experiences and achieved favorable clinical effects. This article summarizes high-quality research from basic science to clinical applications aimed to provide more evidence-based medicine proof for the clinical treatment of IgAN. In summary, qi and yin deficiency accounted for the largest proportion in IgAN patients, and the treatment of IgAN should be based on supplementing qi and nourishing yin. Further, for patients with severe IgAN, the treatment combination of Chinese and Western medicines is better than pure Chinese medicine or hormone therapy. In addition, the pharmacological mechanism of Chinese herbal medicines is mostly based on restoring the immune function, relieving the inflammation damage, and inhibiting proliferation of the glomerular mesangial cells.

show abstract

Triptolide Inhibits Tonsillar IgA Class Switching by Upregulating FDC-SP in IgA Nephropathy

Cited by 4 publications

References 0 publications

Efficacy and Safety of Glycosides of Tripterygium wilfordii Combined with Renin-Angiotensin System in the Treatment of IgA Nephropathy: A Systematic Review and Meta-Analysis

Efficacy and Safety of Glycosides of Tripterygium wilfordii Combined with Renin-Angiotensin System in the Treatment of IgA Nephropathy: A Systematic Review and Meta-Analysis

FDCSP Is an Immune-Associated Prognostic Biomarker in HPV-Positive Head and Neck Squamous Carcinoma

Traditional Chinese medicine in treating IgA nephropathy: from basic science to clinical research

Contact Info

Product

Resources

About